It is a general opinion that the treatment of VTE will be more expensive than the prevention of VTE with prophylactic measures. So, there is need to consider the thromboprophylaxis in our patients who are at high risk of VTE to reduce the overall economic burden in the world. In their study, Gussoni G et al (1) noticed that costs for VTE management (the total median) were around four-times higher than those for VTE prophylaxis (€ 1,348.68 vs € 373.03). This means if we follow the evidence-based protocols for VTE prevention, it could limit the current financial burden of VTE on our health budgets. Many clinicians may not feel this net clinical benefit in their small group of patients to get convinced about the larger role of thromboprophylaxis in the health care systems.
Reference
1). Gussoni G, Foglia E, Frasson S, Casartelli L, Campanini M, Bonfanti M, Colombo F, Porazzi E, Ageno W, Vescovo G, Mazzone A; FADOI Permanent Study Group on Clinical Governance. A real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thromb Res. 2013 Jan;131(1):17-23
No comments:
Post a Comment